As India grapples with the ongoing challenges of the COVID-19 pandemic, a new variant, known as the Cicada variant, has emerged, stirring concern among health officials and the public alike. This variant, classified as BA.3.2 and part of the Omicron family, carries over 70 mutations compared to the original Wuhan strain, with more than 50 of these mutations located in the spike protein alone.

The Cicada variant was first identified in South Africa in November 2024, and since then, it has spread to at least 22 countries, raising alarms about its potential impact on global health. Symptoms associated with this variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash.

Despite the extensive mutations, preliminary assessments indicate that the Cicada variant is not confirmed to cause more severe illness than previous variants. However, the uncertainty surrounding its transmissibility and potential to evade immunity from prior infections or vaccinations remains a pressing concern.

In the United States, the first confirmed case of the Cicada variant was reported in June 2025, and by January 2026, three patients had been confirmed, all of whom recovered. Dr. Robert Hopkins Jr. commented on the situation, stating, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” This highlights the unpredictable nature of viral evolution and its implications for public health.

The CDC has emphasized the importance of monitoring the spread of the BA.3.2 variant, noting that it provides valuable insights into the potential for this new lineage of SARS-CoV-2 to evade existing immunity. As health officials in India and around the world continue to track the Cicada variant, the focus remains on understanding its behavior and impact.

Details remain unconfirmed regarding the real-world severity of illness caused by the Cicada variant, leaving many questions unanswered. The emergence of this variant underscores the need for ongoing vigilance and research as the global community continues to navigate the complexities of the pandemic.

The post Cicada COVID Variant in India: A New Challenge on the Horizon appeared first on The Business News.

The emergence of the cicada COVID variant, scientifically named BA.3.2, has raised alarm bells across the United States as it spreads rapidly, detected in at least 25 states as of February 2026. This heavily mutated strain of SARS-CoV-2 is believed to have the potential to evade immunity gained from vaccinations or previous infections, making it a significant public health concern.

First identified in South Africa in November 2024, BA.3.2 has since made its way to at least 23 countries, with a notable presence in Denmark, Germany, and the Netherlands, where it accounts for approximately 30% of cases. The variant is characterized by an astonishing 70 to 75 mutations in its spike protein, which may compromise the effectiveness of existing vaccines against infection, although they are still expected to provide protection against severe disease.

Dr. Andrew Pekosz, a prominent virologist, emphasized the variant’s unique mutation profile, stating, “It has a lot of mutations that may cause it to look different to your immune system.” This characteristic is particularly concerning as it could lead to a resurgence of COVID-19 cases, despite the ongoing vaccination efforts.

Despite these alarming features, health experts, including Dr. Adolfo García-Sastre, have noted that there is currently no evidence to suggest that BA.3.2 is causing more severe disease or higher hospitalization rates compared to previous strains. Symptoms associated with this variant include cough, fever, sore throat, and gastrointestinal issues, which are consistent with common COVID-19 symptoms.

The World Health Organization has classified BA.3.2 as a ‘variant under monitoring’ since December 2025, highlighting the need for continued surveillance and research. As of now, approximately 3.7% of sewage samples nationwide have shown traces of BA.3.2, indicating its presence in the community.

While the variant’s unusual emergence pattern has drawn comparisons to the lifecycle of a cicada, the reasons behind its resurgence remain unclear. Public health officials are closely monitoring the situation, as the long-term impact of BA.3.2 on public health is still uncertain.

As the situation evolves, vaccination continues to be a critical tool in limiting the spread of BA.3.2. Dr. Pekosz reassured the public, stating, “Vaccination is still going to help limit cases.” However, the effectiveness of current vaccines against this variant is a growing concern.

With BA.3.2 continuing to spread, health authorities urge the public to remain vigilant and adhere to safety measures. Details remain unconfirmed regarding the variant’s full implications, but the potential for increased cases underscores the importance of ongoing research and public health initiatives.

The post Cicada covid variant: The : BA.3.2 Emerges as a New Challenge appeared first on The Business News.